M&A Activity • Nov 28, 2025
M&A Activity
Open in ViewerOpens in native device viewer
Xlife Sciences AG / Key word(s): IPO/Merger
Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown
28.11.2025 / 13:10 CET/CEST
Zurich, 28 th of November 2025: Xlife Sciences AG («Xlife Sciences», SIX: XLS), a leading incubator and value creator in the life sciences sector, provides an update on the ongoing listing process of its portfolio company VERAXA Biotech AG («VERAXA»), in which Xlife Sciences holds approximately 19%. VERAXA previously announced a proposed business combination with Voyager Acquisition Corp. («Voyager», NASDAQ: VACH), a U.S.-listed SPAC, VERAXA Biotech AG filed a registration statement on Form F-4 in July 2025 with the U.S. Securities and Exchange Commission (SEC).
Following a 43-day U.S. government shutdown, during which the SEC was also affected, the SEC has now responded to VERAXA's Form F-4 filing submitted at the end of October. The SEC was unable to respond to VERAXA’s Form F-4 during this time. Subsequently, the SEC responded and VERAXA has filed an amendment to the Form F-4 on November 28, marking another important step forward in the planned business combination with Voyager Acquisition Corp. and VERAXA's intended listing on NASDAQ.
The date of VERAXA's extraordinary general meeting (EGM), which will address the required shareholder approvals of VERAXA for the business combination, is expected to be scheduled in December 2025. Based on the current timeline and assuming customary regulatory progression, Xlife Sciences expects VERAXA Biotech AG to complete its NASDAQ listing in the first quarter of 2026.
Oliver R. Baumann, CEO of Xlife Sciences AG, commented: « We are pleased to see the SEC process advancing swiftly despite the prolonged shutdown. We remain confident in the transaction timeline and in VERAXA's trajectory toward becoming a NASDAQ-listed leader in next-generation oncology therapeutics. »
Further details, including an investor presentation and documentation related to the proposed transaction, are available via the SEC's EDGAR system at www.sec.gov .
*Financial calendar*
| Annual Report 2025 | 28 April 2026 |
| Annual Shareholders Meeting 2026 | 26 June 2026 |
| Half-Year Report 2026 | 24 September 2026 |
Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, [email protected]
Xlife Sciences AG,
Talacker 35,
8001 Zurich,
Switzerland,
Phone +41 44 385 84 60
[email protected] , www.xlifesciences.ch ,
Commercial Register Zurich CHE-330.279.788
Stock Exchange: SIX Swiss Exchange
Advisors
Anne Martina Group is acting as sole M&A advisor to VERAXA. Duane Morris LLP is acting as legal counsel to VERAXA. Winston & Strawn LLP is serving as legal counsel to Voyager. Cantor Fitzgerald is acting as Voyager's capital markets advisor.
About Xlife Sciences AG (SIX:XLS)
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit https://www.xlifesciences.ch
About VERAXA Biotech AG
At VERAXA Biotech AG, we strive to establish the premiere drug discovery and development engine for antibody drug conjugates and other novel antibody-based therapy concepts. Wielding a suite of transformative technology innovations and applying thorough quality-by-design principles in drug discovery, we are accelerating our pipeline of antibody drug conjugates and our novel BiTAC antibody formats into and through clinical development. VERAXA Biotech AG originates from scientific discoveries made at the European Molecular Biology Laboratory (EMBL), a world-leading institute for life science research and ground-breaking enabling technologies. For more information, visit https://www.veraxa.com/
About Voyager Acquistion Corp. (VACH US)
Voyager Acquisition Corp. is a blank check company incorporated in December 2023 as a Cayman Islands exempted company. Headquartered in Brookly, New York, its primary objective is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Led by experienced professionals with a track record in healthcare and life sciences, Voyager seeks to support transformative businesses on their path to becoming publicly listed companies. For more information, visit https://www.voyageracq.com/
Disclaimer
Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.
More information about the Participants in the Solicitation, Non-Solicitation, Forward-Looking Statements and Additional Information can be found in the attached document.
End of Media Release
View original content: EQS News
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | [email protected] |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2237500 |
| End of News | EQS News Service |
2237500 28.11.2025 CET/CEST
Have a question? We'll get back to you promptly.